Co-Founder and Advisor
New York Office | mark.simon@torreya.com | 212.257.5809
Mark Simon, Torreya Co-Founder and Advisor, has 30 plus years experience advising biotech and specialty pharma companies. He has worked on more than 175 financing and M&A transactions totaling over $50 billion in value.
Before co-founding Torreya in 2007, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup, where he covered global pharmaceutical companies, with a focus on large-capitalization players in the US, Europe, and Japan. Prior to his tenure at Citigroup, Mark served as a Managing Director at Robertson Stephens in San Francisco and New York. There, he was involved in raising 45% of all biotech dollars raised in the US from 1999-2001.
Before moving into Investment Banking, Mark was a senior biotech research analyst at Robertson Stephens, where he was named Wall Street All-Star Analyst three years in a row. He began his career as a research associate at Kidder Peabody in New York in 1984, covering biotechnology and health care services companies.
Mark holds a B.A. in history from Columbia College and an M.B.A. from Harvard Business School.
He serves on several boards of philanthropic organizations and for-profit companies.
![]() |
Financing with |
![]() |
$40 Million
March 2019
|
![]() |
Research collaboration and license agreement for RIG-I pathway with |
![]() |
Up to $505 million
December 2018
|
![]() |
Sale of Intrathecal business to |
![]() |
$203 million
March 2017
|
![]() |
Sale of FXR program to |
![]() |
Up to $470 million
January 2015
|
![]() |
Sale to |
![]() |
$658 million
June 2014
|
![]() |
Strategic investment from |
![]() |
$30 million
February 2020
|
![]() |
Acquires royalty interest position for 7 assets from |
![]() |
$15 million
September 2018
|
![]() |
Debt financing for acquisition of Icon Biosciences from |
![]() |
$20 Million
March 2018
|
![]() |
License of Gevokizumab and certain associated IP to |
![]() |
$31 million upfront
August 2017
|
![]() |
Asset sale to |
![]() |
July 2017
|
![]() |
Microbiome partnership with |
![]() |
$2.6 billion
($50 million upfront) January 2017
|
![]() |
Sale of royalties to |
![]() |
$22 million
December 2016
|
![]() |
Sale to |
![]() |
Up to $45 million
($16 million upfront) December 2015
|
![]() |
Sale of biologics manufacturing facilities to |
![]() |
$5 million in cash +
$1 million in stock November 2015
|
![]() |
License of global rights for Anti-TGF-beta antibody program to |
![]() |
Up to $517 million
October 2015
|
![]() |
Sale to |
![]() |
Up to $605 million
July 2015
|
![]() |
Acquisition of |
![]() |
Up to $35 million
October 2014
|
![]() |
License of Pidilizumab to |
![]() |
Up to $335 million
with royalty October 2014
|
![]() |
Financial advisor on follow-on offering |
![]() |
$72.5 million
February 2014
|
![]() |
Sale to |
![]() |
$40+ million with
$10 million upfront January 2014
|
![]() |
Sale to |
![]() |
December 2013
|
![]() |
Sale to |
![]() |
19.9% of shares +
$12 million November 2013
|
![]() |
Advisor on oncology partnership with |
![]() |
$550 million with
$10 million upfront August 2013
|
![]() |
Sale for up to $106 million to |
![]() |
$12 million +
milestones January 2013
|
![]() |
Sale of Fareston® to |
![]() |
$21.7 million
October 2012
|
![]() |
Sale of Amicar® rights to |
![]() |
August 2012
|
![]() |
Sale of Roxicodone® to |
![]() |
August 2012
|
![]() |
Sale of Zipsor® to |
![]() |
June 2012
|
![]() |
Co-promotion for Zipsor® |
![]() |
May 2011
|
![]() |
Advisor in the acquisition of six products from |
![]() |
July 2010
|
![]() |
Advisor to Genentech major shareholder in sale to |
![]() |
$46 billion
March 2009
|
![]() |
Sale to |
![]() |
April 2008
|